ISAL 2019 | MRD monitoring by NGS in AML over time: revealing predictors of relapse
Peter Valk
• 24 Feb 2019
Peter Valk, PhD, of Erasmus University Medical Center, Rotterdam, Netherlands, discusses the relevance of MRD monitoring by next-generation sequencing in acute myeloid leukemia (AML). Dr Valk discusses a study that his group undertook, in which molecular MRD detection took place at multiple timepoints during AML treatment in order to investigate mutations that were or were not predictive for relapse in this setting. Dr Valk highlights the next steps for this interesting research. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
